Charles Ferté

7.8k total citations · 3 hit papers
78 papers, 4.3k citations indexed

About

Charles Ferté is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Charles Ferté has authored 78 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Charles Ferté's work include Cancer Genomics and Diagnostics (21 papers), Radiomics and Machine Learning in Medical Imaging (18 papers) and Lung Cancer Treatments and Mutations (15 papers). Charles Ferté is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), Radiomics and Machine Learning in Medical Imaging (18 papers) and Lung Cancer Treatments and Mutations (15 papers). Charles Ferté collaborates with scholars based in France, United States and Spain. Charles Ferté's co-authors include Jean‐Charles Soria, Christophe Massard, Stéphane Champiat, Laurent Dercle, Aurélien Marabelle, Antoine Hollebecque, Samy Ammari, Éric Deutsch, Charlotte Robert and Roger Sun and has published in prestigious journals such as Journal of Clinical Oncology, Bioinformatics and PLoS ONE.

In The Last Decade

Charles Ferté

74 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

2018 825 citations Roger Sun, Elaine Johanna Limkin et al. profile →
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology

2017 570 citations Elaine Johanna Limkin, Roger Sun et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Charles Ferté

Since Specialization

Citations

This map shows the geographic impact of Charles Ferté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Ferté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Ferté more than expected).

Fields of papers citing papers by Charles Ferté

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Ferté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Ferté. The network helps show where Charles Ferté may publish in the future.

Co-authorship network of co-authors of Charles Ferté

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Ferté. A scholar is included among the top collaborators of Charles Ferté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Ferté. Charles Ferté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors 2024 ·Immunotherapy ·Ben Tran, Mark Voskoboynik, Johanna C. Bendell, Martin Gutierrez, Charlotte Lemech, Daphne Day, Sophia Frentzas, Ignacio Garrido‐Laguna, Nathan Standifer, Fujun Wang, Charles Ferté, Yue Wang, Mayukh Das, Benedito A. Carneiro	5
2	Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium 2024 ·The Lancet Regional Health - Europe ·Maria Alice Franzoi, Arlindo R. Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean, Joana Ribeiro, (unknown), Thomas Grellety, Xavier Artignan, Katell Le Dû, Martina Pagliuca, (unknown), (unknown), Fabrice André, Ethan Basch, Otto Metzger, Charles Ferté, Mario Di Palma, Florian Scotté, Inês Vaz-Luís	15
3	The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling 2024 ·Journal of Medical Internet Research ·Étienne Minvielle, (unknown), (unknown), Philippe Aegerter, Marie Ferrua, Charles Ferté, Henri Leleu, (unknown), Claude Sicotte, Mario Di Palma, (unknown)	0
4	Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases 2023 ·Cancers ·Maximiliano Gelli, Christophe Desterke, (unknown), Valérie Boige, Charles Ferté, Peggy Dartigues, Bastien Job, Géraldine Perkins, Pierre Laurent‐Puig, Diane Goèré, Jacques R.R. Mathieu, Jérôme Cartry, Michel Ducreux, Fanny Jaulin	1
5	The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features 2019 ·Scientific Reports ·Elaine Johanna Limkin, Sylvain Reuzé, Alexandre Carré, Roger Sun, Antoine Schernberg, (unknown), Éric Deutsch, Charles Ferté, Charlotte Robert	78
6	Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma 2019 ·Investigational New Drugs ·Caroline Even, Ulrik Lassen, Jaime R. Merchan, Christophe Le Tourneau, (unknown), Charles Ferté, Francesco Ricci, (unknown), Eunice Yuen, Claire Smith, Gerard J. Oakley, Karim A. Benhadji, Christophe Massard	56
7	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics 2018 ·Clinical Cancer Research ·Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, D. Gandara, Jean‐Charles Soria, René Bruno	53
8	The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy 2017 ·Molecular Cancer Therapeutics ·Céline Clémenson, Cyrus Chargari, (unknown), Michele Mondini, Charles Ferté, Mike F. Burbridge, Valérie Cattan, (unknown), Éric Deutsch	24
9	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study 2017 ·European Journal of Cancer ·Christophe Massard, Isabelle Borget, Françoise Farace, Sandrine Aspeslagh, Marie‐Cécile Le Deley, Christophe Le Tourneau, François‐Clément Bidard, Jean‐Yves Pierga, Véronique Dièras, Paul Hofman, Jean‐Philippe Spano, Charles Ferté, Ludovic Lacroix, Jean‐Charles Soria	18
10	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 breakdown → 2016 ·Clinical Cancer Research ·Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel‐Vinay, Nathalie Chaput, Alexander M.M. Eggermont, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté	867
11	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology 2013 ·Clinical Cancer Research ·Charles Ferté, Andrew D. Trister, Erich Huang, Brian M. Bot, Justin Guinney, Frédéric Commo, Solveig K. Sieberts, Fabrice André, Benjamin Besse, Jean‐Charles Soria, Stephen Friend	33
12	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients 2013 ·Clinical Cancer Research ·Justin Guinney, Charles Ferté, Jonathan R. Dry, Robert McEwen, Gilles Manceau, (unknown), Kai‐Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean‐Charles Soria, Stephen Friend, Jonathan M.J. Derry, Pierre Laurent‐Puig	30
13	IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy 2013 ·Molecular Cancer Therapeutics ·Charles Ferté, Yohann Loriot, Céline Clémenson, Frédéric Commo, Andrea Gombos, Jean‐Emmanuel Bibault, I. Fumagalli, (unknown), Nathalie Auger, (unknown), Cyrus Chargari, Julien Caldéraro, Jean‐Charles Soria, Éric Deutsch	42
14	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials 2013 ·Clinical Cancer Research ·Charles Ferté, (unknown), Antoine Hollebecque, Serge Koscielny, Antonin Lévy, Christophe Massard, (unknown), Brian M. Bot, Carlos Gomez‐Roca, Clarisse Dromain, Samy Ammari, Jean‐Charles Soria	130
15	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review 2013 ·Cancer and Metastasis Reviews ·Jean‐Emmanuel Bibault, I. Fumagalli, Charles Ferté, Cyrus Chargari, Jean‐Charles Soria, Éric Deutsch	35
16	Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models 2012 ·Critical Reviews in Oncology/Hematology ·(unknown), David Olmos, Charles Ferté, Philippe A. Cassier, Andrew Kramar, Alain Duhamel, Nicolas Penel	19
17	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use 2010 ·Nature Reviews Clinical Oncology ·Charles Ferté, Fabrice André, Jean‐Charles Soria	73
18	Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma 2010 ·Annals of Oncology ·Charles Ferté, Benjamin Besse, Éric Dansin, Florence Parent, Marie‐Pierre Buisine, M.C. Copin, Nicolas Penel, Jean‐Charles Soria	8
19	“Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents 2009 ·Investigational New Drugs ·Nicolas Penel, Nicolás Isambert, Pierre Leblond, Charles Ferté, Alain Duhamel, Jacques Bonneterre	20
20	Équipoise clinique et études cliniques randomisées en cancérologie 2009 ·Bulletin du Cancer ·Charles Ferté, Antoine Hollebecque, (unknown), Nicolas Penel	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact